Claudia Trojaniello
Naples, 80131, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 37 publications
Merkel Cell Polyomavirus and DNA Damage Response (DDR): Transcriptional Analysis of DDR Pathways in the Context of Merkel Cell Carcinoma.
Journal: Cancers
Published: April 14, 2026
Circulating thymidine kinase activity predicts survival and optimal treatment sequencing in BRAF-mutated metastatic melanoma in the SECOMBIT trial.
Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: April 13, 2026
Anti-PD-1 Combinations: Triplets and Beyond.
Journal: Current oncology reports
Published: September 24, 2025
Gene-expression signature predicts autoimmune toxicity in metastatic melanoma.
Journal: Journal for immunotherapy of cancer
Published: June 02, 2025
Nature and management of melanoma recurrences following adjuvant anti-PD-1 based therapy.
Journal: European journal of cancer (Oxford, England : 1990)
Published: July 02, 2024
Impact of cemiplimab treatment duration on clinical outcomes in advanced cutaneous squamous cell carcinoma.
Journal: Cancer immunology, immunotherapy : CII
Published: February 29, 2024
The features and management of acquired resistance to PD1-based therapy in metastatic melanoma.
Journal: European journal of cancer (Oxford, England : 1990)
Published: August 27, 2023
Sequencing Targeted and Immune Therapy in BRAF-Mutant Melanoma: Lessons Learned.
Journal: Current oncology reports
Published: March 07, 2023
Discontinuation of anti-PD1 in advanced melanoma: an observational retrospective study from the Italian Melanoma Intergroup.
Journal: European journal of cancer (Oxford, England : 1990)
Published: December 28, 2022
IL-6 as new prognostic factor in patients with advanced cutaneous squamous cell carcinoma treated with cemiplimab.
Journal: Journal of translational medicine
Published: December 12, 2022
Neoadjuvant plus adjuvant combined or sequenced vemurafenib, cobimetinib and atezolizumab in patients with high-risk, resectable BRAF-mutated and wild-type melanoma: NEO-TIM, a phase II randomized non-comparative study.
Journal: Frontiers in oncology
Published: November 24, 2022
Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.
Journal: European journal of cancer (Oxford, England : 1990)
Published: October 22, 2022
Last Updated: 09/26/2026